Company news
Actuate Therapeutics, Inc. (NASDAQ:ACTU) news
Actuate Therapeutics, Inc. news releases on 6ix. Latest, Sep 9, 2026: Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Press releases & updates
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
June 8, 2026
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
May 31, 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 10, 2026
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
May 6, 2026
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
April 13, 2026
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
March 8, 2026
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
March 4, 2026
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 24, 2026
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
January 21, 2026
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 12, 2026
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO...
January 11, 2026
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
January 6, 2026
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
December 18, 2025
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
December 15, 2025
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
September 22, 2025
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
September 11, 2025
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
September 10, 2025
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
September 9, 2025
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
August 25, 2025
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
August 24, 2025
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
August 6, 2025
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
July 17, 2025
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
June 24, 2025
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
June 20, 2025
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 16, 2025
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
June 2, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
May 31, 2025
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
May 22, 2025
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
May 7, 2025
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
May 6, 2025
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
April 30, 2025
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
April 17, 2025
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
February 25, 2025
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
January 6, 2025
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
December 16, 2024
Actuate Therapeutics to be Added to Russell 2000® Index
November 25, 2024
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
November 11, 2024
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
September 22, 2024
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
September 15, 2024
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
September 10, 2024